SynbioTech probiotic reduces yeast infections in pregnant women

SynForU-HerCare is designed to improve the quality of life in pregnant women with vaginal candidiasis

A clinical study in the Journal of Applied Microbiology has reportedly demonstrated SynForU-HerCare, a probiotic product from SynbioTech, is effective in reducing vulvovaginal symptoms and recurrences of vaginal candidiasis (VC) in pregnant women.

SynForU-HerCare is designed to improve the quality of life in pregnant women with vaginal candidiasis (VC), one of the most common health issues affecting women globally. It’s a combination of six probiotic strains isolated from dairy, namely including Lactobacillus plantarum LP115, Lactobacillus helveticus LA25 and Lactobacillus rhamnosus LRH10. The blend has been tested to ensure its quality, efficacy and performance, the company says.

“Most research on probiotics and vaginal candidiasis (VC) primarily emphasised women in general, without specifically targeting pregnant women. While VC may occur randomly in pregnant women; however, studies indicate that a higher prevalence was observed in pregnant women regardless of their age, trimester, parity, occupation and educational levels. When it comes to VC treatment, studies suggest that probiotics are preferred option compared to antifungal drugs because these drugs normally come with side effects such as increased recurrence rate and drug resistance. Thus, we developed further randomised studies to investigate the potential impact of probiotics on prevention of VC particularly in pregnant women.” said Dr San Land Young, Human Healthcare Global Operation Head of SynbioTech.

Seventy-eight subjects at 14-32 weeks of pregnancy with VC completed the double-blind, placebo-controlled randomised 8-week study. The intervention group took lactobacilli probiotics, two capsules per day, for 8 weeks.

The lactobacilli group exhibited a 45% reduction of vulvovaginal symptoms such as irritation, discharge and burning, 31% reduction of worry, 34.6% reduction of the impairment of daily activities attributed to VC at week-8 whereas the placebo group showed no significant changes in emotional stress or in social impacts. The treatment group also reported 38% decreasing in recurrences of emotional stress at week-8 and 33% improvement in social impacts compared to the placebo group.

The results indicate supplementation with the company’s probiotic has the potential to reduce vulvovaginal symptoms, recurrences of VC, and improve emotional and social distress attributed to VC.

Lisa Chen, Marketing Manager at Human Healthcare, SynbioTech said: “There are many probiotics with claims in the market, but science is the key. SynForU-HerCare is backed by robust science and it is our commitment to providing long-term care for women around the globe, thereby make a difference in their life”.